Last reviewed · How we verify
SITAGLIPTIN AND METFORMIN HCL (SITAGLIPTIN, METFORMIN HYDROCHLORIDE)
SITAGLIPTIN AND METFORMIN HCL (generic name: SITAGLIPTIN, METFORMIN HYDROCHLORIDE) is a drug developed by MANKIND PHARMA LTD. It is currently FDA-approved.
SITAGLIPTIN AND METFORMIN HCL is a combination medication used to treat Type 2 Diabetes, as indicated by ClinicalTrials.gov. It works by inhibiting mitochondrial complex I (NADH dehydrogenase) through a small molecule mechanism, as verified by ChEMBL.
At a glance
| Generic name | SITAGLIPTIN, METFORMIN HYDROCHLORIDE |
|---|---|
| Sponsor | MANKIND PHARMA LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Upper respiratory tract infection
- Nasopharyngitis
- Peripheral edema
- Headache
- Hypoglycemia
Key clinical trials
- A Phase III, Randomized, Placebo and Active-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of the Addition of Metformin in Japanese Patients With Type 2 Diabetes Mellitus Who (Phase 3)
- A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycem (Phase 3)
- Prospective, Randomized, Open-label Study With Blinded Endpoint (PROBE Design) to Compare the 72 hr Glycemic Profiles Obtained by Continuous Subcutaneous Glucose Monitoring (CSGM) in Type 2 Diabetic P (Phase 4)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial (NA)
- A Description of Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns Including Initiation, Switching, and Discontinuation (N/A)
- A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Gl (Phase 2)
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes (Phase 3)
- A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SITAGLIPTIN AND METFORMIN HCL CI brief — competitive landscape report
- SITAGLIPTIN AND METFORMIN HCL updates RSS · CI watch RSS
- MANKIND PHARMA LTD portfolio CI
Frequently asked questions about SITAGLIPTIN AND METFORMIN HCL
What is SITAGLIPTIN AND METFORMIN HCL?
Who makes SITAGLIPTIN AND METFORMIN HCL?
What is the generic name of SITAGLIPTIN AND METFORMIN HCL?
What development phase is SITAGLIPTIN AND METFORMIN HCL in?
What are the side effects of SITAGLIPTIN AND METFORMIN HCL?
Related
- Manufacturer: MANKIND PHARMA LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing